MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition

Oncogene

Volumn 31, Issue 41, 2012, Pages 4434-4446

  Astanehe, A ^a   Finkbeiner, M R ^a   Krzywinski, M ^b   Fotovati, A ^a   Dhillon, J ^a   Berquin, I M ^c   Mills, G B ^d   Marra, M A ^b   Dunn, S E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

breast cancer; MNK; RSK; trastuzumab resistance; YB 1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE INTERACTING KINASE 1; PROTEIN KINASE; S6 KINASE; SMALL INTERFERING RNA; TRASTUZUMAB; UNCLASSIFIED DRUG; Y BOX BINDING PROTEIN 1;

ARTICLE; BREAST CANCER; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG SENSITIVITY; GENE TARGETING; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PHOSPHORYLATION; PROTEIN ARRAY ANALYSIS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN-SERINE-THREONINE KINASES; PTERIDINES; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SEQUENCE ANALYSIS, DNA; TRANSCRIPTION, GENETIC; Y-BOX-BINDING PROTEIN 1;

EID: 84867399412     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.617     Document Type: Article

References (52)

1. Astanehe A, Finkbeiner MR, Hojabrpour P, To K, Fotovati A, Shadeo A et al. (2009). The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1. Oncogene 28: 2406-2418.
2. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H et al. (2007). The selectivity of protein kinase inhibitors: a further update. Biochem J 408: 297-315.
3. Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K et al. (1997). Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 3: 447-450. (Pubitemid 27145688)
4. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K et al. (2007). A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395-402. (Pubitemid 47539306)
5. Bianchini A, Loiarro M, Bielli P, Busa R, Paronetto MP, Loreni F et al. (2008). Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells. Carcinogenesis 29: 2279-2288.
6. Buxade M, Morrice N, Krebs DL, Proud CG. (2008). The PSF.p54nrb complex is a novel mnk substrate that binds the mRNA for tumor necrosis factor alpha. J Biol Chem 283: 57-65.
7. Buxade M, Parra JL, Rousseau S, Shpiro N, Marquez R, Morrice N et al. (2005). The mnks are novel components in the control of TNF alpha biosynthesis and phosphorylate and regulate hnRNP A1. Immunity 23: 177-189. (Pubitemid 41169287)
8. Camirand A, Lu Y, Pollak M. (2002). Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit 8: BR521-BR526. (Pubitemid 36119174)
9. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL et al. (1992). Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285-4289.
10. Chrestensen CA, Shuman JK, Eschenroeder A, Worthington M, Gram H, Sturgill TW. (2007). MNK1 and MNK2 regulation in HER2-overexpressing breast cancer lines. J Biol Chem 282: 4243-4252. (Pubitemid 47100950)
11. DaSilva J, Xu L, Kim HJ, Miller WT, Bar-Sagi D. (2006). Regulation of sprouty stability by Mnk1-dependent phosphorylation. Mol Cell Biol 26: 1898-1907.
12. Davies AH, Barrett I, Pambid MR, Hu K, Stratford AL, Freeman S et al. (2011). YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification. Oncogene 30: 3649-3660.
13. Dhillon J, Astanehe A, Lee C, Fotovati A, Hu K, Dunn SE. (2010). The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells. Oncogene 29: 6294-6300.
14. Didier DK, Schiffenbauer J, Woulfe SL, Zacheis M, Schwartz BD. (1988). Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box. Proc Natl Acad Sci USA 85: 7322-7326.
15. Diermeier S, Horvath G, Knuechel-Clarke R, Hofstaedter F, Szollosi J, Brockhoff G. (2005). Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 304: 604-619. (Pubitemid 40321136)
16. Finkbeiner MR, Astanehe A, To K, Fotovati A, Davies AH, Zhao Y et al. (2009). Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene 28: 1421-1431.
17. Foster FM, Owens TW, Tanianis-Hughes J, Clarke RB, Brennan K, Bundred NJ et al. (2009). Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer. Breast Cancer Res 11: R41.
18. Fukunaga R, Hunter T. (1997). MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates. EMBO J 16: 1921-1933. (Pubitemid 27170953)
19. Grzmil M, Morin Jr P, Lino MM, Merlo A, Frank S, Wang Y et al. (2011). MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-beta signaling pathway in human glioblastoma. Cancer Res 71: 2392-2402.
20. Guil S, Long JC, Caceres JF. (2006). hnRNP A1 relocalization to the stress granules reflects a role in the stress response. Mol Cell Biol 26: 5744-5758. (Pubitemid 44134331)
21. Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D et al. (2008). Re-defining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res 10: R86.
22. Halatsch ME, Low S, Mursch K, Hielscher T, Schmidt U, Unterberg A et al. (2009). Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib. Laboratory investigation. J Neurosurg 111: 211-218.
23. Hefner Y, Borsch-Haubold AG, Murakami M, Wilde JI, Pasquet S, Schieltz D et al. (2000). Serine 727 phosphorylation and activation of cytosolic phospholipase A2 by MNK1-related protein kinases. J Biol Chem 275: 37542-37551. (Pubitemid 32004863)
24. Henson ES, Hu X, Gibson SB. (2006). Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic mcl-1 expression. Clin Cancer Res 12: 845-853. (Pubitemid 43259867)
25. Imamura T, Huang J, Dalle S, Ugi S, Usui I, Luttrell LM et al. (2001). Beta-arrestin-mediated recruitment of the src family kinase yes mediates endothelin-1-stimulated glucose transport. J Biol Chem 276: 43663-43667.
26. Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, Fronda A et al. (2009). Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 119: 661-673.
27. Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS et al. (2009). Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15: 429-440.
28. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. (2001). Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93: 1852-1857. (Pubitemid 34048651)
29. Mahalingam M, Cooper JA. (2001). Phosphorylation of mammalian eIF4E by Mnk1 and Mnk2: tantalizing prospects for a role in translation. Prog Mol Subcell Biol 27: 132-142.
30. Martin AP, Miller A, Emad L, Rahmani M, Walker T, Mitchell C et al. (2008). Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation. Mol Pharmacol 74: 807-822.
31. Motoyama AB, Hynes NE, Lane HA. (2002). The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 62: 3151-3158. (Pubitemid 34602408)
32. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA et al. (2004). PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127. (Pubitemid 39485684)
33. Nahta R, Esteva FJ. (2006). HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8: 215.
34. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. (2005). Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65: 11118-11128. (Pubitemid 41713383)
35. Nguyen TL. (2008). Targeting RSK: an overview of small molecule inhibitors. Anticancer Agents Med Chem 8: 710-716.
36. Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA et al. (2007). Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res 13: 4909-4919. (Pubitemid 47294799)
37. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P. (1993). Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The south Australian breast cancer study group. J Clin Oncol 11: 1936-1942. (Pubitemid 23304619)
38. Shattuck DL, Miller JK, Carraway III KL, Sweeney C. (2008). Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 68: 1471-1477. (Pubitemid 351346855)
39. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182. (Pubitemid 17231334)
40. Smith JA, Poteet-Smith CE, Xu Y, Errington TM, Hecht SM, Lannigan DA. (2005). Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res 65: 1027-1034. (Pubitemid 40216465)
41. Stratford AL, Fry CJ, Desilets C, Davies AH, Cho YY, Li Y et al. (2008). Y-box binding protein-1 (YB-1) serine 102 is a downstream target of p90 ribosomal S6 kinase (RSK) in basal-like breast cancer cells. Breast Cancer Res 10: R99.
42. Sutherland BW, Kucab J, Wu J, Lee C, Cheang MC, Yorida E et al. (2005). Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 24: 4281-4292. (Pubitemid 40961781)
43. To K, Fotovati A, Reipas KM, Law JH, Hu K, Wang J et al. (2010). Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res 70: 2840-2851.
44. Treeck O, Zhou R, Diedrich K, Ortmann O. (2004). Tamoxifen longterm treatment in vitro alters the apoptotic response of MCF-7 breast cancer cells. Anticancer Drugs 15: 787-793. (Pubitemid 39281303)
45. Ueda T, Sasaki M, Elia AJ, Chio II, Hamada K, Fukunaga R et al. (2010). Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc Natl Acad Sci USA 107: 13984-13990.
46. Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R. (2004). Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol 24: 6539-6549. (Pubitemid 38944335)
47. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L et al. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726. (Pubitemid 34111379)
48. Waskiewicz AJ, Flynn A, Proud CG, Cooper JA. (1997). Mitogenactivated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J 16: 1909-1920. (Pubitemid 27170952)
49. Wendel HG, Silva RL, Malina A, Mills JR, Zhu H, Ueda T et al. (2007). Dissecting eIF4E action in tumorigenesis. Genes Dev 21: 3232-3237. (Pubitemid 350277750)
50. Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E et al. (2006). Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res 66: 4872-4879.
51. Zhang S, Huang WC, Li P, Guo H, Poh SB, Brady SW et al. (2011). Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 17: 461-469.
52. Zhuang G, Brantley-Sieders DM, Vaught D, Yu J, Xie L, Wells S et al. (2010). Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res 70: 299-308.